

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
AstraZeneca (durvalumab, olaparib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality Cancer Black Care	Board of Community Health Councils in Wales
Cancer Equality	British National Formulary
Cancer 52	Care Quality Commission
Endometriosis UK	Department of Health, Social Services
Eve Appeal	and Public Safety for Northern Ireland
Helen Rollason Cancer Charity	Healthcare Improvement Scotland
	Medicines and Healthcare products
M ' ''' O O (Regulatory Agency
	 National Association of Primary Care
Maggle's Centres Marie Curie	National Pharmacy Association
	NHS Confederation
 Peaches womb Cancer Trust South Asian Health Foundation 	Scottish Medicines Consortium
0 ' 1' 111 111 A11'	Welsh Government
 Specialised Healthcare Alliance Tenovus Cancer Care 	Welsh Health Specialised Services
Wellbeing of Women	Committee
Weinbeing of Worner Womb Cancer Support UK	
Womb Cancer Support of Women's Health Concern	Possible comparator companies
Women's Health Concern	Bristol Myers Squibb (paclitaxel)
Healthcare professional groups	GlaxoSmithKline (dostarlimab)
Association of Anaesthetists	Hospira UK (carboplatin, cisplatin,
Association of Cancer Physicians	paclitaxel)
Association of Surgeons of Great	Inceptua (paclitaxel)
Britain and Ireland	Sandoz (cisplatin)
British Association of Surgical	Seacross Pharmaceuticals (paclitaxel)
Oncology	Teva UK (paclitaxel)
British Geriatrics Society	•
British Gynaecological Cancer Society	Relevant research groups
British Institute of Radiology	Cochrane UK
British Oncology Pharmacy	Genomics England
Association	Institute of Cancer Research
British Psychosocial Oncology Society	MRC Clinical Trials Unit

Provisional stakeholder list for the evaluation of durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317 Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
 British Society for Clinical Cytology British Society for Colposcopy and Cervical Pathology Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians and Gynaecologists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care 	 National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317 Issue date: March 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.